{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:52:15Z","timestamp":1788731535505,"version":"build-2803163510"},"reference-count":45,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>In the 2016 update of the World Health Organization (WHO) classification of hematopoietic neoplasms, BCR-ABL1\u2013like B-acute lymphoblastic leukemia\/lymphoma (B-ALL) is added as a new provisional entity that lacks the BCR-ABL1 translocation but shows a pattern of gene expression very similar to that seen in B-ALL with BCR-ABL1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To review the kinase-activating alterations and the diagnostic approach for BCR-ABL1\u2013like B-ALL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources.\u2014<\/jats:title>\n                    <jats:p>We provide a comprehensive review of BCR-ABL1\u2013like B-ALL based on recent literature and the 2016 update of the World Health Organization classification of hematopoietic neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Several types of kinase-activating alterations (fusions or mutations) are identified in BCR-ABL1\u2013like B-ALL. The main categories are alterations in the ABL class family of genes, encompassing ABL1, ABL2, PDGFRB, PDGFRA (rare), and colony-stimulating factor 1 receptor (CSF1R) fusions, or the JAK2 class family of genes, encompassing alterations in JAK2, CRLF2, EPOR, and other genes in this pathway. These alterations determine the sensitivity to tyrosine kinase inhibitors. As a wide variety of genomic alterations are included in this category, the diagnosis of BCR-ABL1\u2013like B-ALL is extremely complex. Stepwise algorithms and comprehensive unbiased testing are the 2 ways to approach the diagnosis of BCR-ABL1\u2013like B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0194-ra","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T14:49:19Z","timestamp":1571842159000},"page":"150-155","source":"Crossref","is-referenced-by-count":45,"title":["BCR-ABL1\u2013like B-Acute Lymphoblastic Leukemia\/Lymphoma: A Comprehensive Review"],"prefix":"10.5858","volume":"144","author":[{"given":"Sarika","family":"Jain","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of Mississippi Medical Center, Jackson."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Abraham","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Mississippi Medical Center, Jackson."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"2020081300433762600_i1543-2165-144-2-150-b01","unstructured":"Swerdlow\n              SH\n            , CampoE, HarrisNL, et al. \n          WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer;2016."},{"issue":"6","key":"2020081300433762600_i1543-2165-144-2-150-b02","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J"},{"key":"2020081300433762600_i1543-2165-144-2-150-b03","doi-asserted-by":"crossref","first-page":"13331","DOI":"10.1038\/ncomms13331","article-title":"Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia","volume":"7","author":"Gu","year":"2016","journal-title":"Nat Commun"},{"key":"2020081300433762600_i1543-2165-144-2-150-b04","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.04.038","article-title":"Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia","volume":"8","author":"Liu","year":"2016","journal-title":"EBioMedicine"},{"issue":"2","key":"2020081300433762600_i1543-2165-144-2-150-b05","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1101\/gr.209163.116","article-title":"Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP","volume":"27","author":"Qian","year":"2017","journal-title":"Genome Res"},{"issue":"12","key":"2020081300433762600_i1543-2165-144-2-150-b06","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"issue":"8","key":"2020081300433762600_i1543-2165-144-2-150-b07","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/gcc.22464","article-title":"ETV6\/RUNX1-like acute lymphoblastic leukemia: a novel B-cell precursor leukemia subtype associated with the CD27\/CD44 immunophenotype","volume":"56","author":"Zaliova","year":"2017","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"2020081300433762600_i1543-2165-144-2-150-b08","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2020081300433762600_i1543-2165-144-2-150-b09","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/leu.2015.134","article-title":"IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951","volume":"29","author":"Clappier","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2020081300433762600_i1543-2165-144-2-150-b10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020081300433762600_i1543-2165-144-2-150-b11","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG\/Erasmus MC and COG\/St. Jude signatures","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"2020081300433762600_i1543-2165-144-2-150-b12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2020081300433762600_i1543-2165-144-2-150-b13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020081300433762600_i1543-2165-144-2-150-b14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2020081300433762600_i1543-2165-144-2-150-b15","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2020081300433762600_i1543-2165-144-2-150-b16","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2020081300433762600_i1543-2165-144-2-150-b17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"23","key":"2020081300433762600_i1543-2165-144-2-150-b18","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2020081300433762600_i1543-2165-144-2-150-b19","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"19","key":"2020081300433762600_i1543-2165-144-2-150-b20","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2020081300433762600_i1543-2165-144-2-150-b21","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"2020081300433762600_i1543-2165-144-2-150-b22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2020081300433762600_i1543-2165-144-2-150-b23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"2020081300433762600_i1543-2165-144-2-150-b24","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","volume":"129","author":"Reshmi","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2020081300433762600_i1543-2165-144-2-150-b25","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3324\/haematol.2018.204974","article-title":"Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort","volume":"104","author":"Zaliova","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2020081300433762600_i1543-2165-144-2-150-b26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bcmd.2010.07.007","article-title":"Backtracking RAS mutations in high hyperdiploid childhood acute lymphoblastic leukemia","volume":"45","author":"Wiemels","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2020081300433762600_i1543-2165-144-2-150-b27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ng.2532","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt","year":"2013","journal-title":"Nat Genet"},{"issue":"23","key":"2020081300433762600_i1543-2165-144-2-150-b28","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2014-04-531871","article-title":"Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition","volume":"124","author":"Irving","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020081300433762600_i1543-2165-144-2-150-b29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","article-title":"Genetic basis of acute lymphoblastic leukemia","volume":"35","author":"Iacobucci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"2020081300433762600_i1543-2165-144-2-150-b30","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/blood.V126.23.2610.2610","article-title":"Three steps to the diagnosis of adult Ph-like ALL","volume":"126","author":"Fasan","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020081300433762600_i1543-2165-144-2-150-b31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.beha.2018.09.003","article-title":"Why and how to treat Ph-like ALL?","volume":"31","author":"Roberts","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"2020081300433762600_i1543-2165-144-2-150-b32","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","article-title":"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome","volume":"116","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2020081300433762600_i1543-2165-144-2-150-b33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"2020081300433762600_i1543-2165-144-2-150-b34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","article-title":"CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: a single-institution experience","volume":"147","author":"Konoplev","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2020081300433762600_i1543-2165-144-2-150-b35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2018.07.007","article-title":"Philadelphia-like acute lymphoblastic leukemia: diagnostic dilemma and management perspectives","volume":"67","author":"Kotb","year":"2018","journal-title":"Exp Hematol"},{"issue":"7","key":"2020081300433762600_i1543-2165-144-2-150-b36","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2020081300433762600_i1543-2165-144-2-150-b37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"2020081300433762600_i1543-2165-144-2-150-b38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2020081300433762600_i1543-2165-144-2-150-b39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2020081300433762600_i1543-2165-144-2-150-b40","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"issue":"11","key":"2020081300433762600_i1543-2165-144-2-150-b41","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"25","key":"2020081300433762600_i1543-2165-144-2-150-b42","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020081300433762600_i1543-2165-144-2-150-b43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11912-017-0589-2","article-title":"Philadelphia-like acute lymphoblastic leukemia in adults","volume":"19","author":"Herold","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2020081300433762600_i1543-2165-144-2-150-b44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-016-2617-y","article-title":"Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives","volume":"95","author":"Malagola","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"2020081300433762600_i1543-2165-144-2-150-b45","first-page":"554","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype","volume":"15","author":"Wells","year":"2017","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/150\/2500906\/arpa_2019-0194-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/150\/2500906\/arpa_2019-0194-ra.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:46Z","timestamp":1764790606000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/2\/article-p150.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,10,23]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0194-ra","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]}}}